IL317957A - Pyrido[4,3-d]pyrimidine compounds - Google Patents
Pyrido[4,3-d]pyrimidine compoundsInfo
- Publication number
- IL317957A IL317957A IL317957A IL31795724A IL317957A IL 317957 A IL317957 A IL 317957A IL 317957 A IL317957 A IL 317957A IL 31795724 A IL31795724 A IL 31795724A IL 317957 A IL317957 A IL 317957A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- alkylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (25)
1. A compound of Formula (V): (V) or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of: ; R is C alkyl, C alkyl, -(C alkylene)-OH, or -(C alkylene)-OH; R is selected from the group consisting of: - 105 - ; R is Cl or F; R is -(C alkylene)-OH, or C alkyl, wherein R and R are optionally taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O; R represents one or two substituents selected from the group consisting of H, -OH, halogen, -(C-C alkylene)-OH, -CN, -(C-C alkylene)-CN, C‑C alkyl, C‑C cycloalkyl, C‑C fluoroalkyl, C‑C fluorocycloalkyl, and C‑C alkoxy; L is a linker comprising one, two or three members independently selected from the group consisting of -O-, -S-, -NR-, and -CRR-; R, R, and R are each independently H or C‑C alkyl; X is O, N, or S; and l is 1 or 2.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of:
3. . 3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R is: . 20 - 106 -
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is C alkyl, and R is -(C alkylene)-OH.
5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is -(C alkylene)-OH, and R is C alkyl.
6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
7. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Ris:
9. . 9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R is F.
10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein X is O, l is 1.
11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has Formula (VI): . - 107 - (VI)
12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R is C alkyl, and R is -(C alkylene)-OH.
13. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R is -(C alkylene)-OH, and R is C alkyl.
14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
16. A compound of Formula (VII) (VII) or a pharmaceutically acceptable salt thereof, wherein R, R, R, and R are each independently H or C‑C alkyl.
17. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R, R, R, and R are each independently H or methyl.
18. The compound of claim 16 or 17, or a pharmaceutically acceptable salt thereof, wherein the compound is 25 - 108 -
19. . 19. A compound or a pharmaceutically acceptable salt thereof, selected from the group consisting of: and
20. . 20. A pharmaceutical composition comprising a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
21. A compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use as a medicament. 15 - 109 -
22. A compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
23. A compound for use in the treatment of cancer according to claim 22, wherein the cancer is small cell lung cancer (NSCLC), pancreatic cancer, or colorectal cancer.
24. A pharmaceutical combination comprising a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent or a pharmaceutically acceptable salt thereof.
25. A pharmaceutical composition comprising the pharmaceutical combination of claim 24 and at least one excipient.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263358324P | 2022-07-05 | 2022-07-05 | |
| US202263394338P | 2022-08-02 | 2022-08-02 | |
| US202263414939P | 2022-10-11 | 2022-10-11 | |
| US202363502931P | 2023-05-18 | 2023-05-18 | |
| PCT/IB2023/056844 WO2024009191A1 (en) | 2022-07-05 | 2023-06-30 | Pyrido[4,3-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317957A true IL317957A (en) | 2025-02-01 |
Family
ID=87426656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317957A IL317957A (en) | 2022-07-05 | 2023-06-30 | Pyrido[4,3-d]pyrimidine compounds |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4551296A1 (en) |
| JP (1) | JP2025525406A (en) |
| KR (1) | KR20250029954A (en) |
| CN (1) | CN119585286A (en) |
| AU (1) | AU2023302139A1 (en) |
| CA (1) | CA3261000A1 (en) |
| CL (1) | CL2024003699A1 (en) |
| CO (1) | CO2024016875A2 (en) |
| CR (1) | CR20240556A (en) |
| DO (1) | DOP2024000275A (en) |
| IL (1) | IL317957A (en) |
| MA (1) | MA71388A (en) |
| MX (1) | MX2024015001A (en) |
| PE (1) | PE20250259A1 (en) |
| PY (1) | PY2352053A (en) |
| TW (2) | TWI869913B (en) |
| WO (1) | WO2024009191A1 (en) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (en) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel phenol compound or salt thereof |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| US20260200925A1 (en) * | 2021-11-24 | 2026-07-16 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| WO2023172737A1 (en) | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024032703A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| AU2023321005A1 (en) * | 2022-08-12 | 2025-03-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compounds and medical use thereof |
| TW202434606A (en) * | 2022-11-17 | 2024-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fused tricyclic compounds, their preparation methods, and their applications in medicine |
| PE20260006A1 (en) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Cereblon-based KRAS degraders and related uses |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| CN121487738A (en) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | Compositions for inducing RAS GTP hydrolysis and their uses |
| CR20250413A (en) * | 2023-04-05 | 2025-11-06 | Pfizer | Pyrido[4,3–d]pyrimidine compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| KR20260019479A (en) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Combination therapy for RAS-related diseases or disorders |
| CN121194980A (en) * | 2023-05-16 | 2025-12-23 | 和记黄埔医药(上海)有限公司 | Tricyclic compounds and their uses |
| EP4724445A1 (en) | 2023-06-06 | 2026-04-15 | Kumquat Biosciences Inc. | Substituted heterocycles and uses thereof |
| EP4735451A1 (en) | 2023-06-30 | 2026-05-06 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN121889155A (en) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | RMC-6291 for the treatment of RAS protein-related diseases or disorders |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (en) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Small molecule inhibitors of KRAS protein |
| AU2024404270A1 (en) * | 2023-12-19 | 2026-07-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Fused tricyclic compound and medical use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202608896A (en) * | 2024-04-30 | 2026-03-01 | 大陸商和記黃埔醫藥(上海)有限公司 | Antibody-drug conjugate and use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| TW202615038A (en) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119874616B (en) * | 2025-03-28 | 2025-05-30 | 四川美域高生物医药科技有限公司 | An organic intermediate and its preparation method and application |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
| SI2242771T1 (en) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
| SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| MX2016017393A (en) | 2014-07-01 | 2017-09-05 | Pfizer | Bispecific heterodimeric diabodies and uses thereof. |
| HUE057285T2 (en) | 2015-04-13 | 2022-04-28 | Pfizer | Therapeutic antibodies and their uses |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| US11589667B2 (en) | 2016-11-16 | 2023-02-28 | Wink Robotics | Deformable end effectors for cosmetic robotics |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN111148762A (en) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | Antibodies and molecules that immunospecifically bind to BTN1a1 and therapeutic uses thereof |
| JP7234142B2 (en) | 2017-06-02 | 2023-03-07 | ファイザー・インク | Antibodies specific for FLT3 and uses thereof |
| MA49772A (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | STING THIOPHENE BENZO [B] AGONISTS FOR CANCER TREATMENT |
| EP3964516A4 (en) * | 2019-04-28 | 2023-01-11 | Genfleet Therapeutics (Shanghai) Inc. | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL APPLICATION |
| CN114615981B (en) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | KRAS G12D inhibitors |
| CN113980032B (en) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | Fused tetracyclic derivative, preparation method thereof and application thereof in medicines |
| EP4262807A4 (en) * | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| CN117083281A (en) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | Pyrimidoheterocyclic compounds and their applications |
| TW202315626A (en) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | Pyrimidine-fused cyclic compound and preparation method and use thereof |
| CN118019746A (en) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | Polycyclic fused ring derivatives and uses thereof |
-
2023
- 2023-06-30 MA MA71388A patent/MA71388A/en unknown
- 2023-06-30 CN CN202380051793.7A patent/CN119585286A/en active Pending
- 2023-06-30 PE PE2024002870A patent/PE20250259A1/en unknown
- 2023-06-30 JP JP2024576355A patent/JP2025525406A/en active Pending
- 2023-06-30 WO PCT/IB2023/056844 patent/WO2024009191A1/en not_active Ceased
- 2023-06-30 CR CR20240556A patent/CR20240556A/en unknown
- 2023-06-30 KR KR1020257003513A patent/KR20250029954A/en not_active Withdrawn
- 2023-06-30 EP EP23744558.0A patent/EP4551296A1/en active Pending
- 2023-06-30 CA CA3261000A patent/CA3261000A1/en active Pending
- 2023-06-30 AU AU2023302139A patent/AU2023302139A1/en active Pending
- 2023-06-30 IL IL317957A patent/IL317957A/en unknown
- 2023-07-04 TW TW112124839A patent/TWI869913B/en active
- 2023-07-04 TW TW113147938A patent/TW202513571A/en unknown
- 2023-07-04 PY PY202302352053A patent/PY2352053A/en unknown
-
2024
- 2024-12-02 CL CL2024003699A patent/CL2024003699A1/en unknown
- 2024-12-03 MX MX2024015001A patent/MX2024015001A/en unknown
- 2024-12-09 CO CONC2024/0016875A patent/CO2024016875A2/en unknown
- 2024-12-30 DO DO2024000275A patent/DOP2024000275A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202409047A (en) | 2024-03-01 |
| CA3261000A1 (en) | 2024-01-11 |
| AU2023302139A1 (en) | 2024-12-19 |
| TWI869913B (en) | 2025-01-11 |
| MX2024015001A (en) | 2025-01-09 |
| CO2024016875A2 (en) | 2024-12-19 |
| PY2352053A (en) | 2025-03-06 |
| TW202513571A (en) | 2025-04-01 |
| KR20250029954A (en) | 2025-03-05 |
| EP4551296A1 (en) | 2025-05-14 |
| CL2024003699A1 (en) | 2025-04-11 |
| JP2025525406A (en) | 2025-08-05 |
| MA71388A (en) | 2025-04-30 |
| CR20240556A (en) | 2025-01-29 |
| CN119585286A (en) | 2025-03-07 |
| DOP2024000275A (en) | 2025-01-31 |
| PE20250259A1 (en) | 2025-01-29 |
| WO2024009191A1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI869913B (en) | PYRIDO[4,3-d]PYRIMIDINE COMPOUNDS | |
| CA2959688C (en) | Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin | |
| EP2854796B1 (en) | Combinations of a vascular disrupting agent and a hypoxia-targeting agent for use in the treatment of cancer | |
| EP4004002B1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| CN103797001B (en) | Benzothiazole compounds and their pharmaceutical applications | |
| AU2018308871A1 (en) | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer | |
| JP2016172739A5 (en) | ||
| EA023646B1 (en) | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-c]QUINAZOLINE SALTS | |
| JPH02212435A (en) | Method for treating endotoxin shock in mammalia | |
| KR940005566A (en) | Quinoline compounds | |
| JP2021102643A5 (en) | ||
| WO2013103738A1 (en) | Napthalene acetic acid derivatives against hiv infection | |
| JP2015500885A5 (en) | ||
| TW202038947A (en) | Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses | |
| JP2008500366A5 (en) | ||
| JP2004502732A5 (en) | ||
| WO2018133661A1 (en) | Novel boric acid derivative and pharmaceutical composition using same | |
| KR20240004657A (en) | Use of medicine in the treatment of neoplastic diseases | |
| JP2018529737A5 (en) | ||
| KR20210070978A (en) | Compounds and uses thereof | |
| CN104557939A (en) | Hydrochloride of pyrrolo-pyrazine compound and application of hydrochloride | |
| US9738613B2 (en) | Substituted 1,2,3-triazoles as antitumor agents | |
| ES2928666T3 (en) | Pyridinethiones, their pharmaceutical compositions and their therapeutic use for the treatment of proliferative, inflammatory, neurodegenerative or immune-mediated diseases | |
| RU2441021C2 (en) | Lysobactinamides | |
| US20150376216A1 (en) | Sugar-analog phosphorus-containing heterocycles having an anti-metastatic activity |